Keyphrases
Targeted Therapy
100%
Mepolizumab
100%
Anti-interleukin 5
100%
Eosinophilic Diseases
100%
Atopic Eczema
60%
Eosinophils
60%
Hypereosinophilic Syndrome
60%
Eosinophilic Gastrointestinal Disorders
60%
Interleukin-5 (IL-5)
40%
Treatment Options
20%
Therapeutic Effect
20%
Cell Surface
20%
Therapeutic Target
20%
Bone Marrow
20%
Monoclonal Antibody
20%
Apoptosis
20%
Promising Treatment
20%
Receptor Complex
20%
Bronchial Asthma
20%
Randomized Double-blind Placebo-controlled Study
20%
Asthma
20%
Clinical Improvement
20%
Asthma Treatment
20%
IL-5 Receptor
20%
Compassionate Use
20%
Selective Reduction
20%
Eosinophil Cells
20%
Nasal Polyposis
20%
Churg-Strauss Syndrome
20%
Anti-IL-5 Antibody
20%
Elevated Eosinophils
20%
Medicine and Dentistry
Disease
100%
Targeted Therapy
100%
Eosinophilic
100%
Eosinophil
100%
Interleukin 5
100%
Mepolizumab
100%
Atopic Dermatitis
60%
Hypereosinophilic Syndrome
60%
Eosinophilic Gastrointestinal Disorder
60%
Asthma
40%
Receptor
20%
Cytokine
20%
Programmed Cell Death
20%
Cell Surface
20%
Therapy Effect
20%
Nasal Polyp
20%
Placebo-Controlled Study
20%
Treatment of Asthma
20%
Churg-Strauss Syndrome
20%
Compassionate Use
20%
Monoclonal Antibody
20%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Interleukin 5
100%
Mepolizumab
100%
Asthma
60%
Atopic Dermatitis
60%
Hypereosinophilic Syndrome
60%
Eosinophilic Gastrointestinal Disorder
60%
Therapeutic Effect
20%
Churg Strauss Syndrome
20%
Receptor
20%
Cytokine
20%
Placebo-Controlled Study
20%
Nose Polyp
20%
Monoclonal Antibody
20%
Immunology and Microbiology
Mepolizumab
100%
Interleukin 5
100%
Asthma
60%
Eczema
60%
Eosinophil
60%
Eosinophil Granulocyte
40%
Cell Surface
20%
Monoclonal Antibody
20%
Churg-Strauss Syndrome
20%
Cytokine
20%